Commercial Credit Report for Serodus AS

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Serodus AS is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Serodus AS
Heia 8
Phone: +47 22958191p:+47 22958191	OSLO, 0268 Norway	Ticker: 0QEX0QEX

Business Summary

Serodus AS is a Norway-based mid-stage clinical company. It is focused on treatments for patients with diabetic kidney disease. The Company has a dedicated focus on the treatment of patients with T2D and diabetic kidney disease and has a broad, chemically diversified basket of compounds. Serodus’s goal is to mature its SER150 candidate and subsequently enter partnerships for the remaining development, regulatory market approvals and global marketing. SER150 significantly reduced the key biomarker of kidney disease, albumin (protein) in urine, after only four weeks of treatment in patients with varying initial amounts of albumin in urine. SER150 was well tolerated, and no safety concerns were observed. The Company has two wholly owned subsidiaries, Serodus ApS (renamed from Phlogo) in Copenhagen, Denmark, and Serodus (AUS) Pty Ltd in Melbourne, Australia.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2018	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Board	SoerenElmann Ingerslev		1/1/2023	7/8/2013
Chief Executive Officer	EvaSteiness		5/21/2014
Chief Financial Officer	HenrikMordhorst		1/1/2019
Director	Ole P.Nordby	62	7/8/2013	7/8/2013
Director	Terri B.Sebree	65	4/24/2014	4/24/2014

Business Names

Business Name
0QEX
SER

General Information

Number of Employees:	2	(As of 9/30/2023)
Outstanding Shares:	44,502,062	(As of 9/30/2016)
Stock Exchange:	OSL
Fax Number:	+47 22604427

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN